Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Neuropharmacology. 2011 May 30;61(4):699–706. doi: 10.1016/j.neuropharm.2011.05.013

Figure 2.

Figure 2

Isoflurane potency for inhibition of total 4-aminopyridine-evoked glutamate and GABA release from isolated nerve terminals. Data for inhibition of (A) 4AP-evoked release and (B) veratridine (VTD)-evoked release (by 10 μM or 20 μM VTD) were fitted to sigmoidal concentration-effect curves to determine IC50 values (mean ± SEM). Statistical comparisons between cerebral cortex (Cx), hippocampus (Hip), striatum (Str) and spinal cord (SC) (***P < 0.001), between glutamate and GABA release (†P < 0.05; ††P < 0.01; †††P < 0.001), and between 4AP- and VTD-evoked release from cortex (n.s.) were analyzed by comparing logIC50 values of sigmoidal curve fits by F-test.